 BioCryst Pharmaceuticals Inc NASDAQ: BCRX reported a first-quarter loss of 0.36, wider than the consensus loss of 0.27 and deeper than the EPS loss of 0.24 reported a year ago mainly driven by higher expenses. The companys Q1 sales of 19.10 million beat the consensus estimate of 8.89 million, compared to 4.8 million posted in Q1 of 2020. 